UPDATE: Goldman Sachs Upgrades Myriad Genetics to Buy on Expanded Portfolio, Domestic Bias
Goldman Sachs raises its rating on Myriad Genetics (NASDAQ: MYGN) and raises its price target from $27 to $29.
Goldman Sachs says, "We upgrade shares of MYGN to Buy from Neutral for four reasons: (1) we believe the recent reimbursement concerns are overdone and believe that the patent debate does not pose near/medium term risk; (2) MYGN's highly US-focused business offers several new product catalysts; (3) we see potential for improved capital allocation to drive share outperformance in 2H; and (4) we believe the scarcity value of established Diagnostics assets warrants an M&A premium in our price target methodology."
MYGN closed at $23.77 on Friday.
Latest Ratings for MYGN
|Aug 2016||Gabelli & Co.||Downgrades||Buy||Hold|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.